Member Info for Smokinjoe03

15% is a bit strong for a differed CFC in Canada, this will bounce of £3 I belive

I think you'll find the weakness is a broader issue affecting most sequencing genome companies based on general market conditions and current budgets affected by interest rates etc...not a specific ONT issue, I'm a total believer in their nanopore technology, which as far as I know is unique and the only genuine platform.

YHAL - You said look at the Chinese nanopore sequencing competition, but I'm pretty certain ONT hold the patents on this technology so would be interested to know what Chinese company you are referring to?

The most significant detractors to performance in the period were Ocado, Alnylam and Oxford Nanopore.

Oxford Nanopore flagged that tepid academic research budget growth, alongside a curtailing of its UAE genome sequencing project, would act as a drag on 2024 revenue growth. These issues as unhelpful but transient. Ultimately, they distract from what we think is the compelling evidence building to support its novel technology in clinical and applied sequencing use-cases, previously off- limits to DNA sequencing from a cost or practicality perspective. The company has an increasing pool of industry partners and collaborators with whom it is looking to develop new applications eg Biomerieux in antimicrobial resistance, Lonza in quality testing of mRNA therapeutics and Guy's & Thomas' NHS Trust to investigate rapid identification and analysis of pathogens in intensive care units. In time, such opportunities could support a market opportunity far bigger for DNA analysis than that currently represented by the conventional academic-skewed research market.

BAILLIE GIFFORD EWI IT assessment of ONT as a top 10 holding in their financial reports yesterday.

I think we working with China too!

https://nanoporetech.com/news/news-oxford-nanopore-technologies-and-leading-china-based-diagnostic-companies-collaborate

I see Ilumina and PAC up 5% and 13% on Nasdaq ladt night, meanwhile in London!!

Can't blame tech for considering moving stateside, Ocado another tech in my book that is also considerably undervalued and under appreciated.

I sometimes get the feeling (I hope irrationally) it's kept low just to entice big investors to take out the company.

I only see this as another buying opportunity, it won't be here long I suspect

I also thought it was 6th June but it is 9th June, so Monday the gloves are off for interested parties...and it this price we may see some early action.

Https://www.google.com/amp/s/www.einnews.com/amp/pr_news/716132294/genomics-services-market-poised-for-explosive-growth-reaching-usd-111-billion-by-2031

I agree there will certainly be consolidation and imho the long read sequencing of Oxford Nanopore is the jewel in the crown, especially with the only portable device on the market.

Short tracker shows zero disclosed positions, so unlikely

Excellent news and further progress in taking market share away from Illumina and being one of the key long read platforms of choice.

Long reads is the future for Sequencing make no mistake.

Fog - yes the odds maybe 10 fold, but it's a potential 10/1 shot for a reason, there is a genuine threat to future existence from either Ukraine government (through the courts) or Putin via war.

Rocket - agree and it's still at a very silly price!

Obviously hugely popular event based on it being a total sellout and prices looking expensive, certainly not putting anyone off going

I think right now the market and players are focused on income shares, ones that reap a dividend for example and growth and innovation companies have been largely forgotten, however I expect that to change very soon once interest rates start to fall and growth companies like Oxford nanopore come strongly into focus, especially with 6th June IPO protection ending.

Buying increasing, momentum turning very positive imo

At our current lowly price, the market values ONT at £983m, but when you factor in they have zero debt and £480m in cash/cash equivalents then the market have a £500m value essentially.

With its cash burn around £70m py, it has a cash runway of about 6-7 years, but expects to be profitable in 2027, with revenues expected to be 6-15% higher this year than last, which was £169.7m in 2023.

Someone is mopping up these cheap shares, next few weeks I'm expecting a continuous rise into the £1.40's region, especially as the June date gets closer

I agree directors purchased over half million pounds between them at around £1,28, only 6 weeks back.

I honestly believe this hugely innovative company is at huge risk to be snapped UP by someone like Illumina who are struggling for growth and could view Oxford as future competitor due to their superb portable devices, long read technologies and growing user base.